Published

Commentary: Evidence-Informed Recommendation to Achieve Approximate Parity in the Allowed Number of Doses for Common Psychedelics.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Journal of psychoactive drugs
Date: 2024-01-01
Source: PubMed
DOI: 10.1080/02791072.2023.2201244
PubMed: 37061961

Authors

Thomas KL Jesse R Mehtani NJ Mitchell JM Anderson BT

Watch author

Derived topics and classifications

psilocybin Clinical Trial Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.The International journal on drug policy · 2022-01-01 With great power comes great responsibility: Promise and caution in the new psychedelic renaissanceBrain Disorders · 2025-09-23 Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelicsFrontiers in Psychiatry · 2024-11-06 Molecular Imaging Study of Harmine/DMT: a Basic Research ApproachClinicalTrials.gov · 2025-03-19